As GRB2 has been suggested to be a therapeutic target for cancers by targeting its SH2/SH3 domains [48, 49], it may be interesting to further study the synergistic anticancer effect of GRB2 and NSUN2-mediated m5C modification in ESCC. This evidence concerns the gene GRB2 and esophageal squamous cell carcinoma.